Navigation Links
Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Date:2/6/2009

can have a significant impact on patient lives. Nplate represents a potentially high value option for these patients."

The EU approval of Nplate is based on data from two separate placebo-controlled Phase 3 studies, demonstrating that platelet counts were raised and sustained in 83 percent of patients for both splenectomised and non-splenectomised groups when treated with Nplate. Additionally, patients treated with Nplate were able to reduce or discontinue concomitant medications such as corticosteroids which are often not well tolerated. Nplate patients also used far less "emergency" medications such as IVIG and Win-Rho, whose effects are transient.

Upon completion of the Phase 3 studies almost 90 percent of patients elected to subsequently enroll into the Nplate long term extension study which demonstrated that Nplate continued to effectively increase and sustain platelet counts. In this open label long term extension study the average treatment period was 76 weeks and the longest duration of treatment was 204 weeks.

Key findings from the extension study showed platelet counts of Nplate-treated patients were increased from baseline by 20,000 platelets per microliter more than 80 percent of the time in 47 percent of patients and more than half the time in 67 percent of patients.

"Amgen is committed to advancing the discovery and development of new therapies for grievous illnesses where there is an unmet need," said Willard Dere, M.D., senior vice president and international chief medical officer at Amgen. "The European approval of Nplate is the result of more than 15 years of research and represents an important biotechnology milestone as it is the first approved peptibody, an innovative platform for delivering targeted therapies."

About Adult ITP

In patients with ITP, platelets - or blood elements needed to prevent bleeding - are destroyed by the patient's
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , August 22, 2014 ... http://www.researchandmarkets.com/research/x34qgv/global_laboratory ) has announced the addition of ...  report to their offering.       ... an essential instrument for any modern science ... weighing of materials. It can be broadly ...
(Date:8/22/2014)... DUBLIN , August 22, 2014 /PRNewswire/ ... ) has announced the addition of the  ... to their offering.       (Logo: ... room with a sterile environment in a ... It is equipped with technically advanced equipment, ...
(Date:8/22/2014)... WASHINGTON , Aug. 22, 2014 ... Obamacare that modify the religious "accommodation" but still ... drugs that have an abortifacient effect, including Plan ... "week after pill"). The Obama Administration also announced ... religious, closely held, for-profit corporations. The ...
Breaking Medicine Technology:Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Liberty Institute: Government "Accommodation" Still Requires Employers To Facilitate Coverage Of Abortifacient Drugs 2
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Back-to-school time provides ... that fits into the family schedules, an expert suggests. ... child,s school year can also be the start of ... Richards, a professor of kinesiology at the University of ... release. With kids, extracurricular activities likely to build ...
(Date:8/22/2014)... 22, 2014 Dayton Children's Hospital broke ground ... part of a $141 million campus renewal. Renderings ... were unveiled to the public. , The new patient ... will create a campus that meets the needs of patients, ... care spaces will embody Dayton Children’s unique patient care mission ...
(Date:8/22/2014)... CLEVELAND Renal artery stenting to open blockages ... have historically been excluded from modern clinical trials, ... e-published in Catheterization and Cardiovascular Interventions ... Interventions (SCAI). , University Hospitals Case Medical Center,s ... and Professor of Medicine, Case Western Reserve University ...
(Date:8/22/2014)... Menstrual leaks risk stains and embarrassment, especially ... that there needed to be a better way to ... in design variations, the Safety Net optimizes protection during ... embarrassment and promotes peace of mind. The pad serves ... original design was submitted to the Fort Lauderdale office ...
(Date:8/22/2014)... who use reduced-nicotine cigarettes don,t smoke more to make ... a new study. This means they don,t inhale ... The month-long study included 72 adult smokers, aged ... emission levels of 1.2 milligrams (mg) each for one ... the next three weeks. In each of those ...
Breaking Medicine News(10 mins):Health News:With Kids in School, Parents Can Work Out 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2
... response to the growing,demand for solutions to ... United,States, a group of entrepreneurs has established ... consulting,firm with over 25 years experience in ... implement pharmaceutical care, and,"Inspire Pharmacists to Practice ...
... Quantify Competitive Treatment Landscape and Support Model-Based Drug ... ... 27 Pharsight,Corporation (Nasdaq: PHST ), a leading provider of ... that it has licensed its public-source Type II,Diabetes meta- database to ...
... Oxygen Community Praises Congressman for Formally Opposing Deep,Cuts ... March 26 Pacific Pulmonary,Services - Ukiah Center, ... and services to more than 200 patients in ... Thompson (CA-1st) to,meet with patients, physicians and technicians ...
... Actuaries Unveil Election 2008 Resources for Voters on ... The American Academy of,Actuaries said the most ... address the program,s long-term financing issues.,According to the ... income from payroll taxes, and Medicare must,rely also ...
... in 2008, -- IND filing for liquid formulation NGX-1998 expected in first half of ... ... under EMEA review for neuropathic pain ... Calif., March 26 NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused on developing ...
... Hillenbrand,Industries, Inc. (NYSE: HB ) (the "Company") announced ... in connection with its previously,announced cash tender offer to ... Notes due 2009 (CUSIP No. 431573AD6). The tender offer ... February 29, 2008 (the,"Offer to Purchase") and the related ...
Cached Medicine News:Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 2Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 3Health News:Pharsight Signs New Diabetes Meta-Database Customer 2Health News:Pharsight Signs New Diabetes Meta-Database Customer 3Health News:Ukiah Home Oxygen Therapy Patients and Physicians Meet with Congressman Mike Thompson to Share Benefits of Quality Home Oxygen Care 2Health News:Ukiah Home Oxygen Therapy Patients and Physicians Meet with Congressman Mike Thompson to Share Benefits of Quality Home Oxygen Care 3Health News:Medicare Trustees' Report Highlights Need for Reform 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 8Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: